Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

14.21 -0.14 (-0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Gapping stocks in Tuesday's session ↗
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? ↗
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments. 
Via Benzinga
News headline image
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
From Rallybio Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
From Rallybio Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
From Rallybio Corporation
Via Business Wire
News headline image
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Which stocks have an unusual volume on Monday? ↗
Unusual volume stocks are being observed in Monday's session. 
Via Chartmill
News headline image
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints ↗
Rallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential. 
Via Benzinga
News headline image
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
From Rallybio Corporation
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.